Mr. John Blackwood is a retired senior executive with a strong track record of success with over 40 years of international experience in the in-vitro diagnostics industry, having held senior positions at both start up and multinational corporations. Since retiring in 2019 Mr. Blackwood has been advising companies developing Sars-CoV-2 tests as part of the National Institute of Health’s RADx Tech Program, and prior to that Mr. Blackwood served as senior vice president of Products and Services of Beckman Coulter Diagnostics, a Danaher Company, responsible for five business units generating over $3B in revenue.

In addition, Mr. Blackwood has led research and development at Siemens Medical, and Business Development at Bayer corporation, as well as other positions during his career. A results oriented, decisive leader, Mr. Blackwood has expertise in product development, strategic planning, strategic marketing, operations, quality assurance and M&A integration. Mr. Blackwood holds a Master of Business Administration from Worcester Polytechnic Institute, a Master of Science from Northeastern University and a Bachelor of Science from the University of Massachusetts at Amherst

Dr Carney received his Ph.D. in Medical Microbiology and Infectious Diseases, Thomas Jefferson Medical School and from 1978-1982 was a Harvard/NIH Fellow in the Dept of Infectious Diseases at Mass General where he trained in virology and was one of the early scientists investigating HIV immunological responses. In 1982, Dr Carney joined DuPont Medical Products. Dr Carney was the first to discover and patent the circulating extracellular domain of HER-2. In 1991, Dr Carney joined Oncogene Science as Vice President R&D and eventually became President of Oncogene Science Diagnostics.

When the company was acquired by Bayer Diagnostics and Bayer Healthcare (BHC) and Dr. Carney continued as President and Head of the Oncogene Science. In 2001, Dr Carney received the Otto Bayer Medal from BHC for the discovery of the HER-2 protein and blood test. At Oncogene Science, Dr. Carney was responsible for R&D, GMP/ISO manufacturing, QMS and international commercialization of numerous blood based and tissue-based biomarkers to guide targeted oncology therapies.

In addition to leading the team that obtained FDA clearance of serum HER-2 as a Class 2 IVD, Dr Carney was responsible for a new CPT code and has published over 250 articles and abstracts and has been awarded over 30 patents. In 2010, Dr Carney joined On-Q-ity as CSO and in 2011 became CEO. Dr Carney and his team developed a unique and proprietary platform which captured circulating tumor cells based on physical size and affinity capture. In Feb 2012, Dr Carney re-joined Wilex (formerly Oncogene Science) as CSO and in Sept 2013 became SVP at Nuclea Biotechnologies when Wilex was acquired.

In 2015, Dr Carney Founded Walt Carney Biomarkers Consulting and consults/advises companies with respect to biomarkers for drug development, diagnostic product development, product commercialization, and strategies for biomarker selection in the areas of oncology, immuno-oncology, neurology, and infectious disease.

Dr Carney has designed and implemented biomarker strategies for patient stratification and monitoring of a variety of personalized cancer therapies, including small molecule therapies, Mab-based immunotherapies such as checkpoint inhibitors (Keytruda), anti-HER-2 therapies (Trastuzumab), or immunotherapies such as autologous T cells. During this time, Dr Carney has also advised start-up biotechnology companies on investor presentations, fundraising, and product positioning strategies. Dr Carney has also provided insight and guidance with respect to product development and commercialization strategies, according to FDA and CLIA guidelines.

Dr. Andrew Cornwell is the Associate Director of the Case-Coulter Translational Research Partnership (CCTRP) in the Department of Biomedical Engineering at Case Western Reserve University. In this role, he works directly with the Program’s awardees to ensure the projects are moving efficiently toward patient care, and also interacts on the Program’s behalf with strategic partners in industry, finance, and management.

Andy earned a PhD in Biomedical Engineering from Case Western Reserve University and performed brain recording research for several years before becoming more involved in ways to accelerate and facilitate academic technology transfer.

Alongside his role with the CCTRP, Andy serves as the Director for Industrial and Strategic Collaborations at the Cleveland FES Center, where he works to find homes for neurotechnology intellectual property coming out of the FES Center, and also maintains strong industrial ties to ensure strategic alignment between clinical needs, market realities, and research priorities.

Anthony Curro is an accomplished business executive and entrepreneur, with over 35 years of experience in life sciences, technology, & finance. Currently, he is the CEO of Immplacate, Inc. an emerging biotechnology firm involved in cell therapies related to immune disorders. He is also a Board member of Xylyx Bio. He has held various senior level positions with global responsibilities, which include medical device powerhouse Guidant, where he was involved in various aspects of the cardiovascular portfolio of products. He has specialized capabilities in sales, marketing, finance, operations, HR, R&D, and strategy. Anthony holds an MBA from Columbia Business School.

Frank DeBernardis has 35 years of medical device experience in the cardiovascular, orthopedic, and aesthetic market segments. He has been the founder of numerous medical device start-ups. Frank was named Entrepreneur of the Year 1993, New Jersey Life Sciences: Inc. Magazine and served as Executive Vice President Meadox Medical, Inc., Vice President Marketing and Sales for PhysioControl and was a National Sales Manager for Medtronic. Frank is a co-founder of Nascent Enterprises LLC which partners with physician inventors to commercialize disruptive therapeutic devices that improve outcomes at reduced costs. Frank is also Co-founder of Gore Range Capital, LLC a venture firm focused on early-stage medical technology commercialization. Frank also serves on the board of Peconic Landing.

Vijay Dhaka believes in creating patient impact through innovation. Over his 20+ career in healthcare technology he has managed company strategy, fundraising, product development, intellectual property, QMS implementation, manufacturing and operations scale up. Vijay is currently CEO and co-founder of CADflow.ai, an automated workflow solution that use AI to dramatically reduce the time and complexity to design patient specific medical prosthetics.

Previously, Vijay held the position of Chief Business Officer of INBRACE, a personalized medical device company. As a founding team member, he co-led fundraising from first money through Series C, raising over $70 million in venture capital. As a consultant at McKinsey & Co. he focused on medical device, pharma, and hospital systems driving innovation through strategy, organizational transformation, and private equity due diligence.

Vijay Dhaka began his career in product development and pre-commercial launch preparation at venture-backed Class II and Class III medical device companies, with combined exits over $1 billion including: VNUS Medical Technologies (IPO; acquired by Covidien), Adiana Inc. (acquired by Cytyc, currently Hologic), and Oratec Interventions (acquired by Smith+Nephew). In addition to his current role at CADflow Vijay is a Board Member of KLOwen Braces, innovative company offering low cost customized orthodontics, a Board Member at the PHASE ONE Foundation, a non-profit focused on de-risking innovative cancer treatments, and is an Advisory Board members of University Lab Partners, a wet lab incubator supporting the entrepreneurial ecosystem of Orange County, CA. Vijay is a graduate of the MIT Sloan School of Management with an MBA in Strategy and holds a BS in Biomedical Engineering from the University of California, San Diego

Michael Harsh is a Portfolio Executive for the National Institutes of Health(NIH)Rapid Acceleration of Diagnostics (RADx) COVID-19 Response Program anda co-founder and Chief Product Officer of Terapede Systems, a digital X-raystartup that focuses on developing an ultra- high resolution medical flat panel X-raydetector. He co-founded Terapede in 2015.Prior to Terapede, Mr. Harsh had a 36-year career with General Electric (GE).

He held numerous positions within GE and served as Vice President and Chief Technology Officer of GE Healthcare, an $18billion division of GE, where he led its global science and technology organization and research and development teams in diagnostics, healthcare IT and life sciences. In 2004, Mike was named Global Technology Leader–Imaging Technologies at the GE Global Research Center, where he led the research for imaging technologies across the company as well as the research associated with computer visualization and superconducting systems. Additionally, Mr. Harsh is a member of the boards of directors of, Compute Health (NYSE: CPUH-UN), Endra Life Sciences (NASDAQ: NDRA), Imagion Biosystems (IBX.AX), and EmOpti as well as being a member the Radiological Society of North America (“RSNA”), Research & Education Foundation Board of Trustees.

He had previously served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is also a McKinsey Senior Advisor and a consultant in the medical device industry. Mr. Harsh is a graduate of Marquette University, where he earned a bachelor’s degree in Electrical Engineering. He holds numerous U.S. patents in the field of medical imaging and instrumentation. In 2008, Mr. Harsh was elected to the American Institute for Medical and Biological Engineering College of Fellows for his significant contributions to the medical and biological engineering field.

Rachael Hagan is the CEO of NephroDI Therapeutics and a recognized leader with a demonstrated track record of commercializing early-stage technology out of universities. Ms. Hagan is experienced in promoting emerging technologies and businesses to investors with a strong record of identifying, planning, and implementing strategic partnerships. Ms. Hagan formerly served as the Managing Director of the Coulter Translational Partnership Fund (CTPF), an evergreen fund providing $1.5M a year for investments at both Emory University/Georgia Tech and previously at the University of Washington.

Beyond providing capital, she evolved the Coulter Fund into a team-based approach that provided a rich resource for advancing translational projects to clinical adoption. Ms. Hagan managed, conceived and implemented investment processes and procedures that brought business discipline to academic environments. She served as interim management on all investments. She actively participated with innovators and co-investors on operational, funding, growth and exit strategies culminating in the formation of more than 57 start-up companies, twenty-three (23) of which raised over $170M in total funding and introduced new products to the market. Ten (10) products were licensed directly to established medical device companies.

Ms. Hagan has provided expert advice on medical technology investment to early-stage funds and angel investors, including Keiretsu Forum Northwest, Wings, Seraph Capital Network, Johns Hopkins University, Seattle Children’s Hospital, Imperial College London, and University of Calgary. Ms. Hagan has an M.Sc. in Medical Regulatory Affairs and was a lecturer at the University of Washington’s School of Pharmacy Master program for Medical Regulatory Affairs. She has advised, coached, and collaborate with numerous entrepreneurs to develop business models, identify and pitch to potential investors, structure funding, and grow the resulting emerging businesses.

Charles (Charlie) Giordano is an experienced executive with over 35 years of industry experience (30 years with GE Healthcare (GEHC)). Over the course of his career, his roles have spanned from engineering development and innovation to new product program management, engineering management, and culminating with over 15 years of experience as Chief Technology Officer (CTO) and Quality and Regulatory Executive in the Imaging as well as the Medical Devices businesses at GEHC.

In these roles, Charlie’s primary responsibility was new product innovation, development, and successful market introduction. Over the course of his long career, Charlie was deeply involved in hundreds of successful new product introductions for the global healthcare markets. As a result of his breadth of experiences, he is not only skilled in product development and market deployment, but also in U.S. Food and Drug Administration (FDA) and global regulations, cross-functional team leadership, inorganic product development business partnerships, and general management of large global technology organizations.

Jaya Ghosh is the Program Director of the University of Missouri Coulter Biomedical Accelerator. She has worked with the MU Coulter Program for the past four years, and is experienced in program and project management. She is also the Lead Program Manager of the Midwest Biomedical Accelerator Consortium (MBArC), an NIH Research Evaluation and Commercialization Hub (REACH). Prior to joining Coulter, Jaya completed a fellowship with the University of Missouri’s Biodesign and Innovation Program where she was part of an exclusive 3-person team that successfully performed hands-on investigation to identify unmet clinical needs, designed, built and tested prototypes of solutions, conducted proof-of-concept studies, and developed market research and business cases to bring biomedical innovations to market. Jaya has a PhD in Bioengineering from Mizzou and a Bachelor of Engineering degree in Instrumentation and Control Engineering from the Manipal Institute of Technology in India. Prior to her PhD, Jaya also worked as a software and testing engineer at Infosys Technologies Limited.

From 2018-2020, Zach has worked as an independent contractor for Garrett Technologies, an ISO 13485 certified medical device development company. While at Garrett, Zach gained broad knowledge about embedded devices, which inspired him to complete a minor in Computer Science while studying Bioengineering in undergrad at the University of Illinois at Urbana-Champaign (UIUC).

Zach also gained great familiarity with medical device standards imposed by regulatory bodies, and what it means to provide quality assurance and exercise quality management measures. Zach graduated in May 2020 from undergrad at UIUC with a strong drive to do meaningful work and to make an impact in the workplace. That same month, Zach joined the NIH’s RADx program, and since then have supported and helped manage dozens of RADx projects with innovative and high performing testing technologies for COVID-19, a few of which have achieved Emergency Use Authorization (EUA) from the FDA while participating in the program. Recently, Zach has been supporting the Independent Test Assessment Program (ITAP) through his role at RADx.

Dr. Shahram Hejazi is a life science investor and entrepreneur with general management experience in both early-stage ventures and large global companies. As Managing Director and CEO, Dr. Hejazi is responsible for the overall leadership and strategic direction of BioAdvance. His areas of investment focus are research tools, devices, diagnostics and digital health. He serves on the boards of Halo Labs Inc., WellTrackOne Inc., Talex Medical LLC, Bainbridge Health LLC, RightAir Inc., Oncora Medical Inc., Wellsheet Inc. and Keriton Inc. He is the Chairman of Philadelphia Pediatric Device Consortium at CHOP. Dr. Hejazi is also the 2014 James Wei Visiting Professor of Entrepreneurship at Princeton University, where he is a part-time faculty and teaches a well-regarded course on the topic of venture capital.

Previously, Dr. Hejazi was the President of Kodak’s life science division (later called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. While holding this position, Dr. Hejazi led the system business to successful double-digit annual growth and directed the launch of a new imaging agent business. Before Kodak, he was the CEO of Zargis Medical Corporation (an early stage medical device company that spun-off from Siemens), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval and product launch- the company was later sold to 3M. Prior to Zargis, Dr. Hejazi was the Head of the Strategic Business Development group at Siemens where he was instrumental in establishing Siemens first corporate venture fund. Earlier in his career, Dr. Hejazi held R&D management positions within the diagnostic imaging and nanotechnology fields at Kodak and IBM, respectively.

In addition to his Board responsibilities at BioAdvance, Shahram is also the Chairman of the advisory board of Integral Molecular Inc. His past Board responsibilities includes FDA Industry Advisory Panel Member for Molecular and Clinical Genetic Devices, Fox Chase Cancer Center, Bioscan Inc., Alpha Innotech Corp. Shahram is the author of over 10 scientific publications and has a PhD in electrical engineering with emphasis in biophysics (SUNY at Buffalo) and an executive business education (Stanford University).

Dr. Ishaque received his PhD in Electrical Engineering from Rensselaer Polytechnic Institute in December 1990. Immediately after graduation he joined GE, where he played leadership roles in the Healthcare space including diagnostic imaging, molecular medicine, patient monitoring, digital solutions and life sciences. He retired from GE Healthcare in 2020 after nearly 30 years with the company. He served as the Chief Innovation Officer for GE Healthcare Imaging and Director of Global R&D in Healthcare for GE Global Research among other positions. Dr. Ishaque is now consulting and mentoring startups and other organizations in technology evaluation, formulation of product-oriented R&D strategy, multigenerational product development, approaches to competitive market positioning and translation to clinical practice and commercial adoption.

Dr. Ishaque is a highly networked executive adept at driving business strategy, R&D initiatives and product excellence in medical imaging and molecular medicine. He has extensive experience in developing new products and solutions from inception to commercialization including hardware, data analytics, assays and systems. He has broad and deep expertise across several technical disciplines including diagnostic imaging physics and systems, ionizing radiation detector technologies, biomedical instrumentation, molecular technologies, contrast media/tracer development, data analytics and artificial intelligence. He also has a keen understanding of clinical unmet needs, technologies and disease pathobiology in aspects of oncology and neurology.

He has been instrumental in driving academic- industry-government research partnerships throughout his career. Dr. Ishaque is a Fellow of AIMBE. He has twenty issued patents and more than twenty invited papers and conference publications. He is widely recognized as an industry leader in Medical Imaging and other healthcare-related areas. He has served on the Scientific Advisory Board and Scientific Review Committee of numerous external and governmental agencies and academic institutions at different times in his career.

Kathie Jordan is the director of the Coulter Translational Research Partnership at Drexel University, where she oversees a portfolio of 30+ technologies in which the program has invested. Prior to joining Drexel, she held the same position at the University of Washington. A scientist by training, she spent her early career studying Drosophila ovarian development and the role of the innate immune pathways in mouse and endothelial models of sepsis, before moving into university technology transfer. She has served as a speaker, panelist, and moderator, on the topic of early stage technology commercialization in the life science space. She holds a Ph.D. in Molecular and Cellular Biology from the University of Washington and a B.S. in Biology from Haverford College.

Jacob Khouri is a Director at Breton Highlands Consulting, where he provides medical technology consulting services to national clients. He currently serves as a Project Facilitator in the NIH RADx COVID-19 diagnostics initiative. Prior to founding Breton Highlands Consulting, Jacob was a paramedic with Grady EMS, one of the highest-volume Emergency Medical Services in the country. Prior to his clinical role, Jacob held technology focused-roles in the nanotechnology and research tool industries. Jacob is a Licensed Paramedic, Certified Flight Paramedic, Certified EMS Instructor, and holds a Bachelor of Science in Biomedical Engineering from Georgia Institute of Technology. He currently lives in Tulsa Oklahoma with his wife and three chickens.

Shubhangi Lal recently served as a Portfolio Manager with the Coulter Translational Program at the University of Pittsburgh. Ms. Lal holds an MBA from the Katz Graduate School of Business, University of Pittsburgh specializing in Technology Commercialization, Marketing & trategy. She received her Master’s in Biological Sciences and a Bachelor’s in Pharmacy from Birla Institute of Technology and Sciences, Pilani, India. Her industry experience includes work as an IP executive with the Confederation of Indian Industry (trade organization) and as a consultant for Frost and Sullivan Innovation Solutions.

She developed strategies for Intellectual Property protection and management for the senior management of client companies. Additionally, she established and managed interdisciplinary innovation teams within client organizations. Ms. Lal’s expertise is in managing interdisciplinary teams comprising engineers, scientists, clinicians, consultants, licensing & finance professionals, entrepreneurs to develop both scientific and business milestones that lead to a translatable event.

Tamara McKenzie has broad experience in the innovation landscape, with an extensive background in university technology translation, proof-of-concept grant program administration and project management, as well as fostering private, corporate and strategic alliances for startup companies. Tamara has served as the GAITS platform portfolio manager for the NIH RADx (Rapid Innovation of Diagnostics) Initiative for the development and deployment of COVID diagnosticssince April 2020. She has previously served as IT/platform manager for C3i, by way of her role as program manager/projectspecialist for the USC-Coulter Translational Partnership Program, which funded translational research at the university, bringing biomedical and clinical research innovations from bench-top to bedside.

In this role, Tamara was responsible for project management, program marketing, recruitment, event coordination, proposal cycle management, and award administration. As project manager, Tamara supported product and business development activities in order to meet project milestones, developing and administering project budgets, recruiting regulatory consultants and business advisors, and assisting teams with opportunities to secure follow-on funding and go-to-market. Tamara came to the Coulter Program with prior experience in intellectual property commercialization from the USC Stevens Center for Innovation, where she supported the New Ventures & Alliances team in making connections between USC innovators and the business community, promoting the development of successful innovations and start-up creation in the life sciences.

Here, she played a key role in records management and reporting for 69 university startups and an additional 64 technologies in the startup pipeline across both physical and life sciences. Tamara provided support to the center’s licensing and compliance teams through MTA processing, invention disclosure triage, IP records management and federal invention reporting through iEdison. She also served as the center’s grant proposal coordinator, as well as the interim manager for the Ideas Empowered Program – providing proof-of-concept funding and entrepreneurship training for innovative commercialization projects.

Rob Newman, MS, MBA, RAC has over 30 years’ experience in the medical device arena. He is an entrepreneurial executive with demonstrated expertise in technology and medicine; extensive experience in developing companies, regulatory strategy and commercialization of novel medical devices. Rob has worked in Engineering, Regulatory Affairs, Clinical Affairs and Quality.

He spent 17 years with GE Medical Systems managing clinical applications development for magnetic resonance imaging. He also has worked at several start-ups in the areas of in- vitro fertilization, robotics, neuromodulation and focused ultrasound surgery. These have been a combination of Class II and Class III devices involving multiple international clinical trials. He recently retired as the Global Head of Regulatory for J&J Diabetes Care.

Rob holds a BS in Biology from the U.S. Air Force Academy, earned a Masters in Clinical Engineering from The Johns Hopkins School of Medicine, and an MBA from the University of Baltimore. Rob lives in Chadds Ford, PA with his family. He is a regular speaker for RAPS, ACRP and other professional training forums. He is also very active in the Rotary International, Angel Flight and other community service projects.

Rifat serves as CEO of Midway Pharmaceuticals and as an advisor to the Wallace H. Coulter Foundation. He serves on the Oversight Committees of the of Emory -Georgia Tech and Drexel Coulter Translational Partners Funds, Managing Partner of RxMP Therapeutics and Mobius Innovations, Director of Atrin Pharmaceuticals and Virion Therapeutics. As Founder and CSO of Cell Pathways, he raised over $140M and took the company public on NASDAQ. He has been featured in Time, Business Week, Forbes and Dateline NBC, has authored over 110 academic publications, and is an inventor on 150+ issued patents. Rifat received his BA from the Johns Hopkins University and MD from University of Wisconsin. He trained in GI at the University of Chicago.

Cindy has 20+ years in FinTech leading company-wide transformational projects. Her last role as VP of Professional Services was to lead multiple teams in delivering technology and managed services to highly regulated global companies. For the last 2+ years, Cindy has been working as a Program Manager on the RADx Team and as a Consultant, assisting startups with hiring, designing and implementing operational processes, and building partnerships.

Dennis Rose is an experienced Information Technology Program Manager with over thirty years of technology-based implementation efforts, performance improvement measures and systems application experience. Dennis has worked in various leadership roles and maintains certifications for Project Management and is an Agile Scrum Master. Dennis resides in the Florida Panhandle and is an avid outdoorsman and is usually taking opportunities for kayaking, trail walking and exploring saltwater fishing in the bays and gulf with his free time.

Dr. Vosburgh joined GE Corporate Research in 1972 and initially worked on a new X-ray Image Intensifier, which was put into production as the Z7954 XRII Tube. He then worked on teams to develop algorithms for the first GE whole body CT scanner. In 1978, Dr. Vosburgh was promoted to research manager and held increasing levels of responsibility over 22 years. He reached the GE Senior Executive Board, and was responsible for several successful product developments; which were (with many collaborators) the Signa-SP open MRI image guided therapy system, medical ultrasound prototypes (key to the Logiq E9 product), angiographic, spectroscopic, and cardiac MRI technology, the imaging systems for the “Open Speed” MRI, the Visualization Toolkit (now widely used for medical imaging research), MRGuided focused ultrasound surgery (now a successful spin-off product in clinical use), open-system software quality methodologies, and mutual-information based metrology systems.

In 2000, he joined the Center for Integration of Medicine and Innovative Technology (CIMIT) and Harvard Medical School, Mass General Hospital. There he created high tech solutions to clinical problems by supporting teams of physicians and engineers.

In 2004, he created and has continued to direct the Clinical Image Guidance Laboratory: CIGL, CIGL’s goal is to bring high technology methods pioneered in radiology to the direct benefit of clinicians. A key contribution of the laboratory has been the development of kinematics-based analysis of operator performance. This has been applied to laparoscopic and endoscopic surgery, and most recently to performance characterization in diagnostic examinations such as colonoscopy (n>37).

Beginning in 2014, Dr. Vosburgh began working with new colleagues on better methods to characterize and support patients with Chronic Obstructive Pulmonary Disease. Dr. Vosburgh also lectures and serves as a coach with the Boston Biomedical Innovation Center and as an independent consultant. Dr. Vosburgh has his doctorate in Physics from Rutgers University and MS (Applied Physics) and BS (Eng. Physics) from Cornell University.

Lisa Waples is the C3i Manager and has been engaged in translational research programs as a consultant with the Wallace H. Coulter Foundation. She is also a consultant to academic departments, non-profit groups, corporations and foundations. Lisa has a biomedical engineering BS and a macromolecular science MS from Case Western Reserve University and a materials science MS from the University of Wisconsin-Madison. She served as associate chair/director of corporate relations, biomedical engineering at Marquette University for 12 years, where she developed and directed biomedical intern/co-op programs, undergraduate curricula, industry continuing education programs, and entrepreneurial programs. Prior to her time in academia, Lisa was an engineer at BF Goodrich.

Over 30 years of in-depth experience with the entire product life cycle, from ideation to end-of-life. Optimization of Product Development Resource Allocation. Global/Large-Scale New Product Development and Introduction Process definition and optimization. Project Schedule Management, Global Scaling and Confidence-Level simulation. World-class Charting and Metrics Development to drive results.

Expert knowledge of Six Sigma, DFx, QFD, FMEA, Process Optimization, Product Value Optimization. Broad computer-systems and artificial intelligence knowledge. MBA, University of Georgia. Masters of Science in Engineering from Florida Atlantic University majoring in genetic algorithms/artificial intelligence and process simulation/optimization. PDMA New Product Development Professional (NPDP) certification. Pragmatic Marketing Certified Product Manager. PMI certified Portfolio Management Professional (PfMP) and Project Management Professional (PMP).